Detalles de la búsqueda
1.
Evolutionary histories of breast cancer and related clones.
Nature;
620(7974): 607-614, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37495687
2.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med;
388(22): 2058-2070, 2023 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256976
3.
Non-surgical ablation for breast cancer: an emerging therapeutic option.
Lancet Oncol;
25(3): e114-e125, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38423057
4.
Time-series blood cytokine profiles correlate with treatment responses in triple-negative breast cancer patients.
Br J Cancer;
130(6): 1023-1035, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38238427
5.
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
Oncologist;
29(3): e319-e329, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37971418
6.
Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: propensity score matching and inverse probability of treatment weighting analysis.
Breast Cancer Res Treat;
204(2): 261-275, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38123790
7.
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Breast Cancer Res Treat;
2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38767786
8.
Quantitative analysis of the effect of docetaxel-induced edema on quality of life in patients with breast cancer and related factors: a prospective cohort study.
BMC Womens Health;
24(1): 165, 2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38454375
9.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol;
24(1): 77-90, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493792
10.
Oncobiology and treatment of breast cancer in young women.
Cancer Metastasis Rev;
41(3): 749-770, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35488982
11.
Discovery of lipid profiles in plasma-derived extracellular vesicles as biomarkers for breast cancer diagnosis.
Cancer Sci;
114(10): 4020-4031, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37608343
12.
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Cancer Sci;
114(1): 221-226, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36168844
13.
Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
Oncologist;
28(1): e77-e81, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36342342
14.
Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry.
Breast Cancer Res Treat;
201(3): 397-408, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37479943
15.
Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
Breast Cancer Res Treat;
201(3): 409-415, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37480384
16.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat;
202(3): 485-496, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676450
17.
An exploratory study for tuft cells in the breast and their relevance in triple-negative breast cancer: the possible relationship of SOX9.
BMC Cancer;
23(1): 438, 2023 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37179317
18.
Radiotherapy versus low-dose tamoxifen following breast-conserving surgery for low-risk and estrogen receptor-positive breast ductal carcinoma in situ: an international open-label randomized non-inferiority trial (TBCC-ARO DCIS Trial).
BMC Cancer;
23(1): 865, 2023 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37710198
19.
A multiparametric approach to predict triple-negative breast cancer including parameters derived from ultrafast dynamic contrast-enhanced MRI.
Eur Radiol;
33(11): 8132-8141, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286791
20.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol;
53(3): 203-211, 2023 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36484305